Annual Cash & Cash Equivalents
$813.00 K
-$49.13 M-98.37%
December 31, 2023
Summary
- As of February 8, 2025, ENLV annual cash & cash equivalents is $813.00 thousand, with the most recent change of -$49.13 million (-98.37%) on December 31, 2023.
- During the last 3 years, ENLV annual cash & cash equivalents has fallen by -$4.86 million (-85.67%).
- ENLV annual cash & cash equivalents is now -98.37% below its all-time high of $49.95 million, reached on December 31, 2022.
Performance
ENLV Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.77 M
-$975.00 K-26.02%
September 30, 2024
Summary
- As of February 8, 2025, ENLV quarterly cash and cash equivalents is $2.77 million, with the most recent change of -$975.00 thousand (-26.02%) on September 30, 2024.
- Over the past year, ENLV quarterly cash and cash equivalents has increased by +$801.00 thousand (+40.64%).
- ENLV quarterly cash and cash equivalents is now -95.90% below its all-time high of $67.67 million, reached on March 31, 2022.
Performance
ENLV Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ENLV Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -98.4% | +40.6% |
3 y3 years | -85.7% | -78.9% |
5 y5 years | -91.7% | -78.9% |
ENLV Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -98.4% | at low | -95.9% | +241.0% |
5 y | 5-year | -98.4% | at low | -95.9% | +241.0% |
alltime | all time | -98.4% | +456.9% | -95.9% | +926.7% |
Enlivex Therapeutics Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $2.77 M(-26.0%) |
Jun 2024 | - | $3.75 M(+95.9%) |
Mar 2024 | - | $1.91 M(+135.3%) |
Dec 2023 | $813.00 K(-98.4%) | $813.00 K(-58.8%) |
Sep 2023 | - | $1.97 M(-43.0%) |
Jun 2023 | - | $3.46 M(-73.7%) |
Mar 2023 | - | $13.14 M(-73.7%) |
Dec 2022 | $49.95 M(+345.9%) | $49.95 M(+29.6%) |
Sep 2022 | - | $38.55 M(+91.3%) |
Jun 2022 | - | $20.15 M(-70.2%) |
Mar 2022 | - | $67.67 M(+504.1%) |
Dec 2021 | $11.20 M(+97.5%) | $11.20 M(-49.4%) |
Sep 2021 | - | $22.15 M(+75.6%) |
Jun 2021 | - | $12.61 M(+208.4%) |
Mar 2021 | - | $4.09 M(-27.9%) |
Dec 2020 | $5.67 M(+43.7%) | $5.67 M(+36.8%) |
Sep 2020 | - | $4.15 M(-59.2%) |
Jun 2020 | - | $10.16 M(-55.2%) |
Mar 2020 | - | $22.67 M(+474.1%) |
Dec 2019 | $3.95 M | $3.95 M(-27.5%) |
Sep 2019 | - | $5.45 M(-62.6%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2019 | - | $14.55 M(+6.6%) |
Mar 2019 | - | $13.64 M(+40.1%) |
Dec 2018 | $9.74 M(+176.1%) | $9.74 M(+481.6%) |
Jun 2018 | - | $1.67 M(-52.5%) |
Dec 2017 | $3.53 M(-48.7%) | $3.53 M(-14.1%) |
Sep 2017 | - | $4.11 M(-20.5%) |
Jun 2017 | - | $5.16 M(+25.9%) |
Mar 2017 | - | $4.10 M(-40.3%) |
Dec 2016 | $6.87 M(-5.7%) | $6.87 M(+16.0%) |
Sep 2016 | - | $5.92 M(-32.0%) |
Jun 2016 | - | $8.71 M(-8.5%) |
Mar 2016 | - | $9.53 M(+30.7%) |
Dec 2015 | $7.29 M(-31.2%) | $7.29 M(+47.3%) |
Sep 2015 | - | $4.95 M(-45.8%) |
Jun 2015 | - | $9.12 M(+30.1%) |
Mar 2015 | - | $7.01 M(-33.8%) |
Dec 2014 | $10.58 M(+3819.6%) | $10.58 M(-69.0%) |
Sep 2014 | - | $34.13 M(+704.3%) |
Jun 2014 | - | $4.24 M(+1471.5%) |
Dec 2013 | $270.00 K(+84.9%) | $270.00 K |
Dec 2012 | $146.00 K | - |
FAQ
- What is Enlivex Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual cash & cash equivalents year-on-year change?
- What is Enlivex Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Enlivex Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ENLV is $813.00 K
What is the all time high annual cash & cash equivalents for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual cash & cash equivalents is $49.95 M
What is Enlivex Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ENLV annual cash & cash equivalents has changed by -$49.13 M (-98.37%)
What is Enlivex Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ENLV is $2.77 M
What is the all time high quarterly cash and cash equivalents for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly cash and cash equivalents is $67.67 M
What is Enlivex Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ENLV quarterly cash and cash equivalents has changed by +$801.00 K (+40.64%)